Personalized Care Pathway May Ease Mood Symptoms In Epilepsy

What was studied

Researchers tested whether a risk-stratified care pathway could be added to routine epilepsy care for adults who also had clinically relevant symptoms of depression or anxiety.

This was a single-center, assessor-blinded pilot randomized study, done from January 2023 to January 2025. Adults with epilepsy were included if their depression score was PHQ-9 10 or higher or their anxiety score was GAD-7 8 or higher. Participants were assigned 1:1 to either guideline-based usual care or a prespecified risk-stratified stepped-care pathway. The pathway used a multimodal risk score based on electrophysiological, neuroimaging, pharmacogenomic, and clinical features to inform tiered monitoring and supportive interventions. Outcomes were assessed at 3 and 6 months.

What they found

The risk-stratified pathway was feasible to use within routine clinical workflows. Compared with usual care, participants in the intervention group showed greater improvement in depressive symptoms and quality of life at 6 months. There were also favorable trends in seizure outcomes and treatment tolerability. Multimodal biomarker measures showed directionally consistent changes over follow-up. However, the authors describe all efficacy and biomarker findings as exploratory.

Limits of the evidence

This was a pilot study and all efficacy and biomarker findings were considered exploratory. It took place at only one center, so the results may not apply to all epilepsy clinics or patient groups. The abstract does not give the number of participants, the exact size of benefit, or details about the supportive interventions. The findings do not establish causal efficacy and are not enough to warrant immediate changes to clinical practice.

For families and caregivers

This study suggests that it may be possible to build more personalized monitoring and supportive care into epilepsy care for adults who also have depression or anxiety symptoms. The early results are encouraging, but they are preliminary and exploratory. Families should not take this study as proof that the pathway works or as a reason to change care on its own.

What to watch next

The abstract supports further evaluation in adequately powered multicenter trials to test this pathway more rigorously and to clarify the size and durability of any benefits.

Terms in this summary

pilot study

A small early study done to see if a larger study is practical and to look for early signals.

randomized controlled trial

A study where people are assigned by chance to different groups so the groups can be compared more fairly.

assessor-blinded

The people measuring outcomes did not know which treatment group a participant was in.

risk-stratified

Care is adjusted based on a person's estimated level of risk.

stepped-care

Care is provided in levels or steps, with monitoring and support adjusted as needed.

pharmacogenomic

Using genetic information that may relate to how a person responds to medicines.

PHQ-9

A questionnaire used to measure depression symptoms.

GAD-7

A questionnaire used to measure anxiety symptoms.